手机验证
/
NCI/ADR-RES; NCI.ADR.RES; NCIADR.RES; NCI/ADRRES; NCIADRRES; ADR-RES; MCF-7/ADR; MCF-7/ADR-RES; MCF-7/AdrR; MCF-7/Adr; MCF-7/adr; MCF-7ADR; MCF7-ADR; MCF7ADR; OVCAR-8/ADR; OVCAR8/ADR
/
充足
/
/
/
/
/
乳腺
人乳腺癌阿霉素耐药细胞
人
/
上皮样细胞和成纤维样细胞均有
/
乳腺
复苏发货或干冰冷冻发货
/
贴壁
1 x 10^6 cells/vial/T25
细胞名称:MCF-7/ADR人乳腺癌阿霉素耐药细胞(STR鉴定正确)
产品货号:C1367
培养条件:RPMI-1640+10%胎牛血清+250ng/ml Adr
生长特性:贴壁
细胞形态:上皮样
产品规格:1 x 10^6 cells/vial/T25
产品货号 | 细胞名称 | 中文名称 | 生长特性 | 细胞形态 | 产品规格 |
C1008 | MCF7 | 人乳腺癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1034 | MDA-MB-453 | 人乳腺癌细胞 | 半悬浮 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1064 | Hs 578T | 人乳腺癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1112 | MDA-MB-231 | 人乳腺癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1119 | SK-BR-3 | 人乳腺腺癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1127 | MCF 10A | 人乳腺细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1156 | MDA-MB-468 | 人乳腺癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1162 | BT-549 | 人乳腺管癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1177 | MDA-MB-436 | 人乳腺腺癌细胞 | 贴壁 | 有多核成分的多形细胞 | 1 x 10^6 cells/vial/T25 |
C1199 | HCC1937 | 人乳腺癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1200 | T-47D | 人乳腺管癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1231 | MDA-MB-157 | 人乳腺癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1249 | Hs 578Bst | 人正常乳腺细胞 | 贴壁 | 成纤维样 | 1 x 10^6 cells/vial/T25 |
C1276 | HBL-100 | 人乳腺上皮细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
用户须知:
1、关于货期:除复苏细胞外,承诺货期1周内到(节假日顺延),大多数产品1-3天内发货。细胞产品因需要复苏后进行1-2代传代调整后等待细胞长满,期间进行微生物检测,货期1、2周左右。
2、关于订购:为了保证您的权益,下单前务必联系我司客户服务热线(021-55150076)。
安全性:
所有肿瘤和病毒转染的细胞均视为有潜在的生物危害性,必须在二级生物安全台内操作,并请注意防护。
公司简介:
WheLab 是一家位于上海的高新技术公司,专注于细胞培养和分子生物学资源开发,服务于各大科研院校、医院和医药企业。 公司拥有先进的分子实验室、细胞培养间、液氮罐,收藏了1000+ 种细胞系,来源于ATCC细胞,DSMZ细胞,JCRB细胞,RIKEN细胞,ScienCell细胞等机构。同时包含自主研发建系的各类示踪细胞、耐药株、基因敲除细胞等。实验室可配制基础实验所需的常规试剂,实验室管理规范,细胞株均有STR鉴定和支原体检测,质量保证! 我们拥有国内、美国海归等丰富经验与专业技术的精英团队,秉承“专业、诚信、可靠”为公司宗旨,以合理的价格,完善的服务,提供可靠的产品,为广大客户提供完整的生物细胞技术解决方案。
如果您需要进一步的信息和服务,欢迎联系我们。
联系人:童小姐
电话:15921090068(微信同号)
:2306932016
:021-55150076
官网:https://whelab.com
公司邮箱:info@whelab.com
技术邮箱:tech@whelab.com
地址:上海宝山区呼兰西路129号8号楼4层
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
PubMed=9625176; DOI=10.1093/jnci/90.11.862
Scudiero D.A., Monks A., Sausville E.A.
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
J. Natl. Cancer Inst. 90:862-862(1998)
PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)
PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)
PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)
PubMed=16504380; DOI=10.1016/j.canlet.2006.01.013
Liscovitch M., Ravid D.
A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells.
Cancer Lett. 245:350-352(2007)
PubMed=18304946; DOI=10.1093/nar/gkn089
Demichelis F., Greulich H., Macoska J.A., Beroukhim R., Sellers W.R., Garraway L.A., Rubin M.A.
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.
Nucleic Acids Res. 36:2446-2456(2008)
PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)
PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)
DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)
PubMed=21116879; DOI=10.1007/s12032-010-9747-1
Ke W., Yu P., Wang J., Wang R., Guo C., Zhou L., Li C., Li K.
MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research.
Med. Oncol. 28:S135-S141(2011)
PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)
PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)
PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)
PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)
PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)
PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)
PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)
PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)
PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)
需要更多技术资料 索取更多技术资料
细胞售后说明.pdf 附 (下载 0 次)